Trial Profile

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders:

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Dexchlorpheniramine; Methylprednisolone; Paracetamol
Indications Demyelinating disorders; Paraproteinaemia; Polyneuropathy; Waldenstrom's macroglobulinaemia
Focus Therapeutic Use
Acronyms THERAMAG

Most Recent Events

07 Feb 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
07 Feb 2023 Planned initiation date changed from 1 Jun 2022 to 1 May 2023.
03 Jan 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com